Meta AnalysisID 366
含黄芪的中药联合铂类化疗治疗晚期胃癌的疗效与安全性：一项系统评价与Meta分析
CRD42020203486
This review aims to evaluate the comparative efficacy and safety for the addition of Astragalus-based Chinese medicines combined with Platinum-based chemotherapy and Platinum-based chemotherapy alone for advanced gastric
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 366
- Evidence Id
- 8924
- Core Evidence Id
- 8924
- Source Meta Analysis Id
- 345
- Herb2 Meta Analysis Id
- HBMA000345
- Crd Id
- CRD42020203486
- Title
- Efficacy and Safety of Astragalus-Containing Traditional Chinese Medicine Combined with Platinum-Based Chemotherapy for Advanced Gastric Cancer: A Systemic review and Meta-Analysis
- Review Question
- This review aims to evaluate the comparative efficacy and safety for the addition of Astragalus-based Chinese medicines combined with Platinum-based chemotherapy and Platinum-based chemotherapy alone for advanced gastric cancer (GC) treatment.
- Study Type Included
- Randomized controlled trials (RCTs).
- Condition Being Studied
- Gastric cancer (GC) is the fifth-most commonly diagnosed cancer and the third leading cause of cancer-related death in the world. 70% or 80% of the patients with GC are diagnosed at advanced stage and lost the opportunity for surgical treatment. Platinum-based chemotherapy is widely used in the treatment of advanced GC. However, the side effects and the development of resistance to chemotherapy in clinical practice reveal its limitations and have prompted more attention to be paid to the study of complementary treatments. Traditional Chinese Medicine (TCM) is the most common complementary therapy for cancer treatment and it has been shown to enhance the efficacy and reduce the side effects of anticancer strategies. Particularly, the Astragalus-based Chinese medicine are frequently combined with chemotherapy for advanced GC in clinic.
- Participant
- Patients who had stage III-IV GC and diagnosed by using the histopathological and cytological diagnostic criteria and the TNM staging system were included. And the patients who had received radiotherapy, chemotherapy or other anti-tumor therapy within one month before treatment, with concurrent infection, or other malignant tumors or severe illnesses were excluded. The baseline data of patients in two groups were comparable.
- Animal
- Human Disease Modelled
- Intervention
- The experimental group patients received Astragalus-based herbal therapy combined with platinum-based chemotherapy. Any form of Astragalus (Huang qi) preparation, including water decoction, extracts, granules or injection, etc., regardless of administration route.
- Comparator Control
- The control group patients received platinum-based chemotherapy alone.
- Main Outcome
- Tumor response and survival rate Measures of effect Tumor response will be assessed by using the objective response rate (ORR) and disease control rate (DCR) according to the WHO or RECIST criteria. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) will be used as indicators. CR plus PR is equal to ORR, CR plus PR and SD is equal to DCR. We will express results for pooled outcomes with dichotomous variables using a random effect risk ratio (RR) with 95% confidence interval (CI).
- Outcome Measure
- Additional Outcome
- Quality of life (QOL), Adverse Drug Reactions (ADRs) and the levels of peripheral blood lymphocytes. Measures of effect QOL is considered to be improved when Karnofsky Performance Status (KPS) score is ten points higher after being treated. ADRs are accessed by measuring hematotoxicity (neutropenia, anemia, thrombocytopenia), gastrointestinal toxicity (nausea and vomiting, diarrhea), hepatic or renal dysfunction, neurotoxicity, alopecia and stomatitis, according to WHO Recommendations for Grading of Acute and Subacute Toxicity or NCI Common Terminology Criteria for Adverse Events (CTCAE). The levels of peripheral blood lymphocytes will be assessed by measuring the T-lymphocyte subsets such as the proportion of CD3+, CD3+CD4+, and CD3+CD8+ T cells; the ratio of CD4+/CD8+ T cells; and the proportion of natural killer cells (NK cells). Our additional outcomes are either dichotomous or continuous variables. We will express results for pooled outcomes with dichotomous variables using a random effect risk ratio (RR) with 95% CI. Results for continuous variables will be expressed as mean differences (MD) using a random effect with 95% CI.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Medicine, Chinese Traditional; Stomach Neoplasms
- Contact
- Mengqi Cheng [email protected]
- Organisational Affiliation
- Guang' anmen Hospital http://www.gamhospital.ac.cn
- Funding Source
- National Natural Science Foundation of China (NSFC), No.81673961, 81774294; Beijing Natural Science Foundation: No.7172186.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-08-09
- Registration Date
- 2020-09-09
- Anticipated Start Date
- 2020-07-10
- Anticipated Completion Date
- 2020-12-31
- Title Cn
- 含黄芪的中药联合铂类化疗治疗晚期胃癌的疗效与安全性：一项系统评价与Meta分析
- Title En
- Efficacy and Safety of Astragalus-Containing Traditional Chinese Medicine Combined with Platinum-Based Chemotherapy for Advanced Gastric Cancer: A Systemic review and Meta-Analysis
- Bilingual Status
- complete